Qualigen Therapeutics, Inc. (NASDAQ:QLGN – Get Free Report) shares traded down 7.3% on Wednesday. The company traded as low as $0.9135 and last traded at $0.9458. 269,386 shares changed hands during trading, a decline of 82% from the average session volume of 1,521,488 shares. The stock had previously closed at $1.02.
Qualigen Therapeutics Trading Down 16.9%
The stock has a market cap of $1.33 million, a P/E ratio of -0.10 and a beta of 0.24. The company’s fifty day simple moving average is $1.13 and its 200-day simple moving average is $1.21.
Qualigen Therapeutics Company Profile
Qualigen Therapeutics, Inc (NASDAQ: QLGN) is a clinical-stage biotechnology company focused on developing therapies for cancer and rare diseases. The company’s research programs are based primarily on small-molecule and nucleic-acid technologies intended to target biological mechanisms associated with tumor growth and disease progression.
Its oncology pipeline has included QN-302, an investigational small-molecule inhibitor of the transcription factor FOXM1 being studied for potential use in pancreatic cancer and other solid tumors.
Further Reading
- Five stocks we like better than Qualigen Therapeutics
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
